Plus, news about AbbVie, SynOx, Eli Lilly’s Jaypirca, ImageneBio, Nxera Pharma, Neurocrine and Novartis: Neomorph raises $100M more for molecular glues: San Diego-based Neomorph has
Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as well as diagnostic agents
BioNTech rolled out positive Phase 2 data Monday morning for an antibody-drug conjugate the company hopes can elbow aside Enhertu in certain populations. BioNTech said
Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
Allogene Therapeutics’ CAR-T therapy removed all remaining detectable lymphoma cells in just over half of treated patients, according to an early look at the Phase 2 data.
The Bay Area biotech …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844